SCYNEXIS, Inc.
SCYXSCYNEXIS, Inc. is a biopharmaceutical company focused on developing and commercializing innovative antifungal therapies. It is known for its oral antifungal drug, Brexafemme (ibrexafungerp), which is approved for the treatment of certain fungal infections. The company emphasizes research and development to address unmet medical needs in fungal diseases and expand its portfolio of antifungal agents.
Company News
SCYNEXIS has transferred its BREXAFEMME New Drug Application to GSK, enabling potential regulatory interactions for relaunching the drug for vulvovaginal candidiasis. SCYNEXIS will receive potential net sales milestones and royalties from GSK.
Shares of Resources Connection, Inc. (NASDAQ: RGP) rose sharply in pre-market trading following better-than-expected results for its second quarter. Resources Connection posted quarterly adjusted earnings of 28 cents per share, beating market estimates of 18 cents per share. The company’s quarterly sales came in at $163.1 million versus expect...
Verve Therapeutics (VERV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Use these tips to identify penny stocks opportunities The post Penny Stocks: Technical Approach to Finding Opportunities appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
